Assignee
SHENGHE CHINA BIOPHARMACEUTICAL CO LTD
CN·1 granted patent·16 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
17 records- 0151US2026022190A1Heterodimeric fusion protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0250US2025243287A1Anti-ccr8 antibody or antigen-binding fragment thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0349US2026055188A1Bispecific antibody and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0449US2026028401A1Anti-ilt4 single-domain antibody and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0549US2026055201A1Bispecific antibody and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0649US2025092140A1Bispecific antibody binding to b7h3 and nkp30, and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0748US2024392007A1Heterodimeric protein and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0847US2024327543A1Multispecific antigen-binding protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0947US2024336682A1Multispecific antigen-binding protein and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1046US2025250335A1Antibody against ceacam5 and ceacam6, and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1145US2025320309A1Bispecific antigen binding proteinSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1245US2026049151A1Bispecific antibody binding to tnfr2 and 4-1bbSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1341US2024150460A1Anti-nkp30 antibody and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1441US2025263499A1Anti-cd24 antibody and use thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1540US2025043015A1Anti-tnfr2 single domain antibody, and preparation method therefor and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1640US2025320303A1Anti-tnfr2 antibody and preparation method and application thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1732US12545741B2Anti-PD-1 and IL-15/IL-15Ra multifunctional antibody conjugate, preparation for same, and uses thereofSHENGHE CHINA BIOPHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 10, 2026·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when SHENGHE CHINA BIOPHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →